THE TYSABRI® (NATALIZUMAB) TOUCH® PRESCRIBING PROGRAM

A commitment to patient safety

  • Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH® Prescribing Program
    • Under the TOUCH Prescribing Program, only prescribers, pharmacies, and infusion sites enrolled in the program are able to prescribe, distribute, or infuse TYSABRI. Only patients who are enrolled in and meet all the conditions of the program may receive TYSABRI
    • To enroll in the TOUCH Prescribing Program, prescribers and patients are required to understand the risks of treatment with TYSABRI, including PML and other opportunistic infections, and to review, complete, and sign the Patient-Prescriber Enrollment Form

PML=progressive multifocal leukoencephalopathy.

How to get started with the TOUCH Prescribing Program

If you are already enrolled in the TOUCH
Prescribing Program:

If you are not enrolled:

Call the TOUCH Hotline at 1-800-456-2255
(Available Monday through Friday 8:30 AM to 8:00 PM ET)
OR
Fax 1-800-840-1278

TOUCH On-Line is a valuable resource for your office

Real-Time TOUCH Data

are at your fingertips. Use TOUCH Analytics to customize your query. Data are sortable, exportable, and viewable in graph form

Automated Reminders

help prescribers and practices maintain compliance with the TOUCH Prescribing Program

Summary of Benefits

for each patient with a completed benefits investigation

Streamlined Process

reduces administrative burden of the TOUCH Prescribing Program with fewer phone calls, electronically stored forms, and reduced faxes

Resources for Your Office

to assist in educating patients
and staff

Prescribers must:

  • Review the TOUCH® Prescribing Program prescriber educational materials, including the full prescribing information
  • Educate patients on the benefits and risks of treatment with TYSABRI and ensure that patients receive the Medication Guide, and encourage them to ask questions
  • Determine every six months whether patient should continue on treatment and submit the TYSABRI Patient Status Report and Reauthorization Questionnaire
  • Report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen at 1-800-456-2255 as soon as possible